Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Non-Current Deffered Revenue (2021 - 2025)

Silo Pharma's Non-Current Deffered Revenue history spans 5 years, with the latest figure at $667502.0 for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 9.75% year-over-year to $667502.0; the TTM value through Sep 2025 reached $667502.0, down 9.75%, while the annual FY2024 figure was $721578.0, 9.08% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $667502.0 at Silo Pharma, down from $685527.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $973935.0 in Q2 2021 and bottomed at $667502.0 in Q3 2025.
  • The 5-year median for Non-Current Deffered Revenue is $829731.0 (2023), against an average of $827275.9.
  • The largest annual shift saw Non-Current Deffered Revenue decreased 2.69% in 2022 before it fell 9.75% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $937884.0 in 2021, then fell by 7.69% to $865782.0 in 2022, then fell by 8.33% to $793680.0 in 2023, then dropped by 9.08% to $721578.0 in 2024, then dropped by 7.49% to $667502.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Non-Current Deffered Revenue are $667502.0 (Q3 2025), $685527.0 (Q2 2025), and $703553.0 (Q1 2025).